ISHARES TR - U.S. PHARMA ETF (IHE)

Historical Holders from Q1 2014 to Q4 2025

Type / Class: Equity / U.S. PHARMA ETF
Symbol: IHE
Price per share: $84.72
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 4,719,905
Total reported value: $342,444,031
% of total 13F portfolios: 0%
Share change: -196,053
Value change: -$13,869,438
Number of holders: 150

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

As of 30 Sep 2025, ISHARES TR - U.S. PHARMA ETF (IHE) has 150 institutional shareholders filing 13F forms. They hold 4,719,905 shares. .

Institutional Holders of ISHARES TR - U.S. PHARMA ETF (IHE) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	11,920	$1,002,191	+$55,626			$84.72	4
2025 Q3	4,719,905	$342,444,031	-$13,869,438	$296,772		$72.56	150
2025 Q2	4,968,369	$325,628,195	-$8,276,832		$0	$65.54	140
2025 Q1	4,897,901	$345,371,935	-$38,715,193		$211,680	$70.56	151
2024 Q4	5,455,870	$358,605,853	+$8,069,374		$6,572	$65.72	155
2024 Q3	5,287,897	$373,305,187	-$36,525,906		$0	$70.61	143
2024 Q2	5,821,186	$386,186,234	+$20,443,628		$411,184	$66.32	141
2024 Q1	5,574,758	$377,592,694	+$213,233,143		$366,660	$67.90	138
2023 Q4	1,893,544	$351,167,088	+$240,877,855		$0	$185.40	132
2023 Q3	649,931	$115,057,100	-$5,412,515		$318,564	$176.98	124
2023 Q2	675,400	$121,103,434	-$9,710,803		$411,953	$179.11	116
2023 Q1	729,788	$128,295,664	-$9,783,894	$0	$420,672	$175.28	124
2022 Q4	746,550	$138,876,719	+$8,758,995	$241,969	$651,455	$186.13	126
2022 Q3	691,897	$117,318,733	-$7,558,289	$203,000	$441,000	$169.54	108
2022 Q2	746,690	$143,234,000	+$33,977,360	$0		$191.65	119
2022 Q1	562,474	$109,355,839	+$8,370,033	$233,000		$194.24	116
2021 Q4	520,688	$104,062,861	-$3,381,738			$199.66	106
2021 Q3	535,391	$98,105,652	+$981,064		$6,000	$183.13	107
2021 Q2	528,900	$98,242,898	+$6,457,088			$185.74	98
2021 Q1	494,172	$87,783,779	-$2,263,005		$0	$177.66	99
2020 Q4	506,263	$90,864,669	+$3,773,491		$592,000	$179.44	96
2020 Q3	485,703	$79,461,411	-$9,036,327	$3,000	$728,000	$163.53	91
2020 Q2	543,697	$83,671,119	+$14,088,589	$523,000	$1,554,000	$153.87	88
2020 Q1	451,167	$60,728,977	-$20,537,996	$794,000	$1,144,000	$134.58	91
2019 Q4	598,618	$95,848,471	-$71,199,280	$800,000	$451,000	$160.11	90
2019 Q3	1,049,383	$146,829,601	+$43,818,388	$348,000	$1,000	$139.85	81
2019 Q2	732,338	$110,460,525	+$8,530,469	$0	$2,000	$150.79	83
2019 Q1	675,083	$103,940,428	-$234,018	$231,000	$755,000	$153.97	89
2018 Q4	684,374	$96,343,411	-$28,861,755	$816,000	$3,012,000	$140.76	92
2018 Q3	877,632	$147,307,850	-$909,430	$1,964,000	$3,558,000	$167.84	95
2018 Q2	876,013	$132,605,951	-$9,897,727	$1,180,000	$4,525,000	$151.35	90
2018 Q1	943,594	$139,178,080	-$137,964,573	$605,000	$1,048,000	$147.54	99
2017 Q4	1,847,113	$285,150,847	-$31,401,828	$247,000	$540,000	$154.38	106
2017 Q3	2,025,449	$316,744,114	-$32,562,827	$391,000	$860,000	$156.36	99
2017 Q2	2,239,435	$347,446,485	-$14,535,839			$155.13	92
2017 Q1	2,302,977	$347,593,226	+$60,500,681	$0	$0	$150.94	95
2016 Q4	1,953,627	$276,365,000	+$114,944,238	$1,471,000	$537,000	$141.42	92
2016 Q3	1,080,051	$160,536,000	-$44,259,881	$4,000	$608,000	$149.44	84
2016 Q2	1,360,676	$196,592,354	-$20,528,854		$259,000	$144.40	88
2016 Q1	1,493,303	$204,750,027	-$99,286,057			$136.98	90
2015 Q4	1,915,142	$309,313,814	-$760,352			$161.69	102
2015 Q3	2,164,584	$321,148,738	-$24,117,852			$148.02	102
2015 Q2	2,309,662	$403,905,318	-$49,635,232			$174.82	118
2015 Q1	2,536,179	$437,086,452	+$86,720,565			$172.42	107
2014 Q4	2,053,922	$310,975,960	+$27,141,839			$151.40	101
2014 Q3	1,843,426	$258,684,490	-$10,400,820			$140.35	85
2014 Q2	1,917,703	$259,123,112	-$2,844,651			$135.11	86
2014 Q1	1,947,975	$246,644,151	+$26,495,460			$126.69	85